MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-27-2026
BioXcel Therapeutics Revenue 2011-2026 | BTAI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue BioXcel Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 642 K | 2.27 M | 1.38 M | 375 K | - | 24.3 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.27 M | 24.3 | 933 K |
Quarterly Revenue BioXcel Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 98 K | 120 K | - | 214 K | 1.1 M | - | 341 K | 457 K | - | - | 137 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.1 M | 98 K | 353 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
403 M | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Exelixis
EXEL
|
2.32 B | $ 46.48 | 4.64 % | $ 12.6 B | USA |
 |
Fortress Biotech
FBIO
|
63.3 M | $ 2.5 | 1.63 % | $ 69.8 M | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
1.11 B | $ 28.79 | 1.41 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
10.1 B | $ 27.79 | 0.92 % | $ 17.1 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
7.21 B | $ 8.33 | 0.73 % | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
29.3 K | $ 2.51 | 27.51 % | $ 152 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
203 M | $ 76.27 | 1.36 % | $ 12.2 B | USA |
 |
BioNTech SE
BNTX
|
482 M | $ 95.08 | -0.44 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Kamada Ltd.
KMDA
|
180 M | $ 8.28 | 0.85 % | $ 260 M |  Israel |
 |
Kymera Therapeutics
KYMR
|
39.2 M | $ 85.67 | 3.58 % | $ 7.24 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
1.07 M | $ 13.28 | -1.26 % | $ 1.76 B |  Australia |
 |
INmune Bio
INMB
|
50 K | $ 1.54 | - | $ 38.1 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
167 M | $ 232.25 | -0.02 % | $ 4.25 B | USA |
 |
Liquidia Corporation
LQDA
|
158 M | $ 41.83 | 4.24 % | $ 3.6 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
958 M | $ 22.89 | 2.42 % | $ 3.79 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
521 M | $ 108.2 | 2.26 % | $ 5.43 B | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
MannKind Corporation
MNKD
|
349 M | $ 3.84 | 34.27 % | $ 1.17 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 3.51 | 0.29 % | $ 5.78 M | Israel |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 23.68 | 1.09 % | $ 3.01 B | USA |
 |
Nanobiotix S.A.
NBTX
|
32.6 M | $ 41.17 | 18.39 % | $ 286 B | France |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |